Literature DB >> 22404435

Retrospective evaluation of bleeding tendency and simultaneous thrombin and plasmin generation in patients with rare bleeding disorders.

M Van Geffen1, M Menegatti, A Loof, P Lap, M Karimi, B A P Laros-van Gorkom, P Brons, W L Van Heerde.   

Abstract

Rare bleeding disorders (RBDs) are a heterogeneous group of diseases with varying bleeding tendency, only partially explained by their laboratory phenotype. We analysed the separate groups of RBD abnormalities, and we investigated retrospectively whether the novel haemostasis assay (NHA) was able to differentiate between bleeding tendency. We have performed simultaneous thrombin generation (TG) and plasmin generation (PG) measurements in 41 patients affected with deficiencies in prothrombin, factor (F) V, FVII, FX, FXIII and fibrinogen. Parameters of the NHA were classified based on (major or minor) bleeding tendency. Patients with deficiencies in coagulation propagation (FII, FV and FX) and major type of bleedings had diminished TG (expressed as AUC) below 20% of control. FVII deficient patients only had prolonged thrombin lag-time ratio of 1.6 ± 0.2 (P < 0.05) and normal AUC (92-125%). Afibrinogenemic patients demonstrated PG of 2-29% of normal and appeared to correlate with the type of mutation. Thrombin peak-height (57 ± 16%) was reduced (not significant) in these patients and AUC was comparable to the reference (102 ± 27%). FXIII-deficient plasmas resulted in a reduced thrombin peak-height of 59 ± 13% (P < 0.05) and normal AUC (90 ± 14%). Thrombin peak-height (P < 0.01) and plasmin potential (P < 0.05) were lower in the major bleeders compared with the minor bleeders. These results provided distinct TG and PG curves for each individual abnormality and differentiation of bleeding tendency was observed for thrombin and PG parameters. Prospective studies are warranted to confirm these retrospective results.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22404435     DOI: 10.1111/j.1365-2516.2012.02759.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

Review 1.  Global coagulation assays: a clinical perspective.

Authors:  Ayesha Zia; Sarah H O'Brien
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

2.  Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency.

Authors:  Joline L Saes; Saskia E M Schols; Kathleen F Betbadal; Mark van Geffen; Kitty Verbeek-Knobbe; Sweta Gupta; Brandon M Hardesty; Amy D Shapiro; Waander L van Heerde
Journal:  Haemophilia       Date:  2019-08-30       Impact factor: 4.287

3.  Treatment of patients with rare bleeding disorders in the Netherlands: Real-life data from the RBiN study.

Authors:  Dominique P M S M Maas; Joline L Saes; Nicole M A Blijlevens; Marjon H Cnossen; Paul L den Exter; Ilmar C Kruis; Karina Meijer; Laurens Nieuwenhuizen; Marjolein Peters; Roger E G Schutgens; Waander L van Heerde; Saskia E M Schols
Journal:  J Thromb Haemost       Date:  2022-02-08       Impact factor: 16.036

Review 4.  Assessing Plasmin Generation in Health and Disease.

Authors:  Adam Miszta; Dana Huskens; Demy Donkervoort; Molly J M Roberts; Alisa S Wolberg; Bas de Laat
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.